OVERVIEW

This conference will review the latest medications and therapies in liver treatment and transplantation. The results of trials and real-world data using oral drugs to treat chronic viral hepatitis B and C, non-alcoholic fatty liver diseases, primary biliary cirrhosis, primary sclerosing cholangitis, hepatocellular carcinoma and complications of end-stage liver disease including thrombocytopenia will be reviewed in detail. New Treatments in Chronic Liver Disease is a comprehensive yet concise program for updating physicians on these and other commonly encountered problems in the treatment of liver diseases.

LEARNING OBJECTIVES

After attending this live activity, participants should be able to:

• Cite new therapies for curing Delta Hepatitis, HBV and HCV.
• Discuss potential new treatments for Wilson’s Disease.
• Summarize non-invasive markers and therapies for NAFLD and NASH.
• Evaluate drugs in development for PBC and PSC.
• Employ strategies for treating and managing HCC, ascites and hepatorenal syndrome.

TARGET AUDIENCE

• Hepatologists
• Gastroenterologists
• Infectious Disease Specialists

ACCREDITATION

Scripps Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Scripps Health designates this live activity for a maximum of 10 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

For more information please visit the official event page.